|
WO2009086197A1
|
|
Her-2 diagnostic methods
|
|
WO2009070772A1
|
|
Enhanced method for detecting and/or quantifying an analyte in a sample
|
|
CA2690635A1
|
|
Electrophoretic tag-based in vitro assay to quantify dimerization of p66 and p51 subunits of hiv-1 reverse transcriptase (rt)
|
|
WO2008103490A2
|
|
Methods and compositions for determining altered susceptibility of hiv-1 to protease inhibitor treatment
|
|
US2008187948A1
|
|
Erbb heterodimers as biomarkers
|
|
US2009111127A1
|
|
Surface Receptor Complexes as Biomarkers
|
|
US2010070184A1
|
|
Method for determining resistance of hiv to protease inhibitor treatment
|
|
US2006223107A1
|
|
Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
|
|
WO2006130449A2
|
|
Method for determining resistance of hiv to nucleoside reverse transcriptase inhibitor treatment
|
|
WO2006130477A2
|
|
Methods and compositions for determining resistance of hiv-1 to protease inhibitors
|
|
WO2007021317A1
|
|
Detecting molecular complexes
|
|
EP1856298A2
|
|
Methods and compositions for determining anti-hiv drug susceptibility and replication capacity of hiv
|
|
WO2006089045A2
|
|
Methods and compositions for determining hypersusceptibility of hiv-1 to non-nucleoside reverse transcriptase inhibitors
|
|
WO2006084018A2
|
|
Methods for determining responsiveness to cancer therapy
|
|
WO2006050237A2
|
|
Method and compositions for determining resistance of susceptibility of hiv-1 to stavudine
|
|
WO2006044748A2
|
|
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
|
US2006183110A1
|
|
Methods of evaluating cell surface receptor binding of a patient derived population of viral envelope protein constructs
|
|
WO2006031815A2
|
|
Methods and compositions for proximity assays
|
|
EP2385145A2
|
|
Compostions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
|
|
US7648828B2
|
|
Methods for detecting receptor complexes comprising PI3K
|
